ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
Authors:
Open Access
- 18 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1228894
Abstract
Introduction: Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR) technology to natural killer (NK) cells may offer safe, effective, and affordable therapies that enhance cancer immune surveillance. Methods: Here, we assess the efficacy of clinically usable CAR-engineered NK cell line NK-92/5.28.z against ErbB2-positive RMS in vitro and in a metastatic xenograft mouse model.Results: Our results show that NK-92/5.28.z cells effectively kill RMS cells in vitro and significantly prolong survival and inhibit tumor progression in mice. The persistence of NK-92/5.28.z cells at tumor sites demonstrates efficient antitumor response, which could help overcome current obstacles in the treatment of solid tumors.Discussion: These findings encourage further development of NK-92/5.28.z cells as off-the-shelf immunotherapy for the treatment of metastatic RMS.Keywords
This publication has 51 references indexed in Scilit:
- Treatment of patients with advanced cancer with the natural killer cell line NK-92Cytotherapy, 2013
- Specific gene delivery to liver sinusoidal and artery endothelial cellsBlood, 2013
- Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and PitfallsFrontiers in Oncology, 2013
- Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasPediatric Blood & Cancer, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005Cancer, 2009
- Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcomaCancer, 2007
- Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcomaLaboratory Investigation, 2006
- Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Construction, Bacterial Expression and Characterization of a Bifunctional Single–Chain Antibody–Phosphatase Fusion Protein Targeted to the Human ERBB–2 ReceptorNature Biotechnology, 1992